A 52 Week Open Label Trial of Memantine for Frontotemporal Lobar Degeneration

Frontotemporal Lobar Degeneration Clinical Trial

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00187525
• Other study ID #: NAM-02A
• Status: Completed
• Phase: Phase 4
• First received: September 13, 2005
• Last updated: November 8, 2012
• Start date: May 2004
• Est. completion date: October 2006

Study information

• Verified date: November 2012
• Source: University of California, San Francisco
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

This is a 52-week, multicenter, open label trial of memantine (Namenda) for frontotemporal lobar degeneration (FTLD). The goal is to determine the safety and tolerability of this FDA-approved medication for Alzheimer's Disease in patients with FTLD. Secondary outcome measures include cognitive batteries, rating scales for activities of daily living and neuropsychiatric symptoms. All patients receive the FDA-approved dose of this medication for Alzheimer's disease.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 0
• Est. completion date: October 2006
• Est. primary completion date: October 2005
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 40 Years to 80 Years

Eligibility

Inclusion Criteria:

• Neary et al. Criteria for Frontotemporal Lobar Degeneration

• Age 40 -80

• CDR < 3 or MMSE > 15

• English Speaking

• Study Partner

Exclusion Criteria:

• Concurrent use of antipsychotic drugs or acetylcholinesterase inhibitors

Study Design

Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Frontotemporal Lobar Degeneration

Intervention

Drug:
• Memantine

Locations

Country	Name	City	State
n/a

Sponsors (2)

Lead Sponsor	Collaborator
University of California, San Francisco	Forest Laboratories